4//SEC Filing
Carey John F 4
Accession 0000899243-23-002074
CIK 0001756262other
Filed
Jan 17, 7:00 PM ET
Accepted
Jan 18, 5:58 PM ET
Size
17.8 KB
Accession
0000899243-23-002074
Insider Transaction Report
Form 4
Carey John F
VP of Operations
Transactions
- Sale
Common Stock
2023-01-17$62.48/sh−338$21,118→ 14,683 total - Sale
Common Stock
2023-01-17$63.70/sh−449$28,601→ 14,234 total - Sale
Common Stock
2023-01-17$64.30/sh−114$7,330→ 14,120 total - Exercise/Conversion
Common Stock
2023-01-17$38.46/sh+1,410$54,229→ 15,530 total - Sale
Common Stock
2023-01-17$60.72/sh−63$3,825→ 15,467 total - Sale
Common Stock
2023-01-17$61.77/sh−446$27,549→ 15,021 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-01-17−1,410→ 13,590 totalExercise: $38.46Exp: 2031-02-24→ Common Stock (1,410 underlying)
Footnotes (8)
- [F1]The reported transactions were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $60.12 to $61.07, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $61.18 to $62.17, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $62.18 to $63.17, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $63.19 to $64.18, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F6]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $64.19 to $64.52, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F7]The amount of securities directly owned by the Reporting Person includes 276 shares of common stock acquired under the TransMedics Group, Inc. 2019 Employee Stock Purchase Plan.
- [F8]The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 24, 2021.
Documents
Issuer
TransMedics Group, Inc.
CIK 0001756262
Entity typeother
Related Parties
1- filerCIK 0001774272
Filing Metadata
- Form type
- 4
- Filed
- Jan 17, 7:00 PM ET
- Accepted
- Jan 18, 5:58 PM ET
- Size
- 17.8 KB